Molecular Subtype
Triple-Negative Breast Carcinoma
CI-CAN-00008567TNBCExplore in graph →
417 active trials3 approved drugs8 evidence items
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00008567TNBCExplore in graph →
Clinical trials
950 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (168)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07729956 | A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04) | not yet recruiting | Phase 3 | 436 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07760844 | An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBC(SCHBCC-N0117) | not yet recruiting | Phase 3 | 180 | Fudan University |
| 0 |
| Aug 12, 2026 |
| clinicaltrials |
| NCT07178730 | NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer(ADAPT-TN-IV) | not yet recruiting | Phase 3 | 765 | Women's Cancer Study Group GmbHOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07669610 | An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC(TRIBE) | not yet recruiting | Phase 3 | 140 | Fudan UniversityOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07486687 | Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy(PLANET) | not yet recruiting | Phase 3 | 1,000 | The Netherlands Cancer InstituteOTHER | 0 | Mar 20, 2026 | clinicaltrials |
| NCT07407517 | Adjuvant Intensification for LAR(POLARIS) | not yet recruiting | Phase 3 | 904 | Fudan UniversityOTHER | 0 | Feb 12, 2026 | clinicaltrials |
| NCT07021261 | Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients | not yet recruiting | Phase 3 | 440 | Fudan UniversityOTHER | 0 | Jun 13, 2025 | clinicaltrials |
| NCT06795503 | Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients | not yet recruiting | Phase 3 | 1,462 | Fudan UniversityOTHER | 0 | Jan 28, 2025 | clinicaltrials |
| NCT04301739 | to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC) | not yet recruiting | Phase 3 | 522 | Shanghai Henlius BiotechINDUSTRY | 0 | Mar 12, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Aug 26, 2026source: clinicaltrials